Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
7.5M
-
Number of holders
-
55
-
Total 13F shares, excl. options
-
4.34M
-
Shares change
-
+1.16M
-
Total reported value, excl. options
-
$354M
-
Value change
-
+$99.8M
-
Number of buys
-
32
-
Number of sells
-
-18
-
Price
-
$81.67
Significant Holders of Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) as of Q3 2025
58 filings reported holding MNPR - Monopar Therapeutics - Common Stock, par value $0.001 per share as of Q3 2025.
Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) has 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.34M shares
of 7.5M outstanding shares and own 57.79% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (1.29M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (659K shares), RA CAPITAL MANAGEMENT, L.P. (511K shares), WELLINGTON MANAGEMENT GROUP LLP (231K shares), VANGUARD GROUP INC (208K shares), BlackRock, Inc. (204K shares), DEERFIELD MANAGEMENT COMPANY, L.P. (160K shares), Saturn V Capital Management LP (155K shares), TCG Crossover Management, LLC (153K shares), and ADAR1 Capital Management, LLC (130K shares).
This table shows the top 55 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.